Rebecca Cook
Faculty Member
Last active: 4/15/2019

  1. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL (2013) J Clin Invest 123(3): 1348-58
    › Primary publication · 23391723 (PubMed) · PMC3582135 (PubMed Central)
  2. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC (2013) Cancer Res 73(20): 6164-74
    › Primary publication · 24130112 (PubMed) · PMC3801432 (PubMed Central)
  3. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL (2013) Proc Natl Acad Sci U S A 110(35): 14372-7
    › Primary publication · 23940356 (PubMed) · PMC3761610 (PubMed Central)
  4. Mouse models and anti-HER2 therapies. Hanker AB, Cook RS, Arteaga CL (2013) Oncotarget 4(11): 1866-7
    › Primary publication · 24272818 (PubMed) · PMC3875754 (PubMed Central)
  5. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL, Redente E, Sandahl M, Hunter DM, Strunk KE, Graham DK, Earp HS (2013) J Clin Invest 123(8): 3231-42
    › Primary publication · 23867499 (PubMed) · PMC3726162 (PubMed Central)
  6. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS (2013) J Clin Invest 123(10): 4329-43
    › Primary publication · 23999432 (PubMed) · PMC3784526 (PubMed Central)
  7. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL (2013) Clin Cancer Res 19(3): 610-9
    › Primary publication · 23224399 (PubMed) · PMC3563762 (PubMed Central)
  8. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL (2013) Cancer Res 73(13): 4075-85
    › Primary publication · 23633485 (PubMed) · PMC3702683 (PubMed Central)
  9. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL (2013) Cancer Res 73(20): 6346-58
    › Primary publication · 23966295 (PubMed) · PMC4090144 (PubMed Central)
  10. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS (2012) Proc Natl Acad Sci U S A 109(1): 221-6
    › Primary publication · 22178756 (PubMed) · PMC3252958 (PubMed Central)